Kips Bay Medical
IPO Filing Date: Apr. 8. 2010
Expected IPO Date: Feb. 10, 2011
Amount of Proceeds Sought: ~$25 millionExpected Offering Price: $8 to $10 Expected Number of Shares to Be Sold: ~ 2.75 million Use of Proceeds: To seek regulatory approval to market its eSVS Mesh product in the U.S. and overseas. The company said the product can improve bypass procedures for heart patients.
Expected Ticker Symbol: KIPS (KIPS) (NASDAQ)
Lead Underwriters: Rodman & Renshaw (RODM) and Newbridge Securities Co-Managers: Caris & Company
About the Company: Kips Bay Medical is a medical device company currently in development stage. The company is focusing on developing, manufacturing and commercializing its eSVS MESH product for coronary artery bypass surgeries. The company said the product can improve the long-term results of these surgeries. The company began shipping its eSVS MESH in European Union markets in Jun. 2010 and the United Arab Emirates in Oct. 2010, but hasn't generated significant revenues yet. The U.S. Food and Drug Administration is currently reviewing Kips' application for the product. If granted, Kips Bay would be able to begin U.S. clinical trials for the project. The company expects enrollment in the clinical trials to begin in the first half of 2011. Kips Bay experienced net losses of $3.3 million and $10.1 million in the year ended Dec. 31, 2009 and the nine months ended Oct. 2, 2010, respectively. The company's net loss for the nine months ended Oct. 2 included a non-cash charge of $2.3 million due to a modification in an investor stock purchase option and a $5 million charge in connection with its first milestone payment to Medtronic (MDT), one year after the first sale of its eSVS MESH. The two have an intellectual property agreement over the product. One of the biggest risks about Kips Bay is its limited history. The company expects more losses in the future. Competitors: Kips Bay said there are at least two companies that develop mesh devices for coronary procedures, but none of their products directly compete with Kips'. These companies include Swiss company Alpha Research and Germany company B. Braun. IPO Scorecard:
Actual IPO Date: Feb. 10 Actual Proceeds Raised: $17 million Actual Offering price: $8 Actual Number of Shares Sold: 2.1 million
First Day Closing Price: $7.93 IPO First Day Return: -0.9 >>Search for Highest Dividends by Rate or Yield
|More on Earnings Today's Top Earnings|
>To contact the writer of this article, click here: Andrea Tse. >To follow the writer on Twitter, go to Andrea Tse. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV